• DeferoxamineB Workflows for Iron-Stress Research

  2026-08-18

  DeferoxamineB gives cancer researchers a practical iron-chelation control for separating ferroptosis-related effects from broader oxidative-stress, apoptosis, and autophagy responses. This guide translates the reference study’s metabolic strategy into assay-ready workflows, formulation guidance, and troubleshooting decisions.

• Tiamulin PK/PD: From MIC to Safe Study Design

  2026-08-18

  Tiamulin (Thiamutilin) is examined through a PK/PD lens that connects ribosomal mechanism, Mycoplasma gallisepticum efficacy, assay design, and veterinary exposure control. This evidence-led guide distinguishes validated findings from exploratory anti-inflammatory applications.

• CK2 Phosphorylation Tunes Arabidopsis LOH2

  2026-08-17

  This 2025 study identifies CK2 phosphorylation as a post-translational switch that simultaneously increases Arabidopsis LOH2 ceramide synthase activity and accelerates its ubiquitin-dependent degradation. The resulting balance controls C16 ceramide production, salicylic acid accumulation, programmed cell death, and resistance to fungal and bacterial stress.

• E-64d Workflows for Calpain and Lysoptosis Research

  2026-08-17

  E-64d is a membrane-permeable cysteine protease inhibitor that helps researchers separate calpain- and cathepsin-dependent events from broader cell-death phenotypes. This practical guide covers intracellular dosing, lysoptosis-focused assay design, platelet and seizure-model applications, and troubleshooting strategies that improve mechanistic confidence.

• BCL9 Inhibition Reverses Checkpoint Resistance

  2026-08-16

  Feng and colleagues developed hydrocarbon-stapled peptides that disrupt the β-catenin–BCL9 transcriptional complex and suppress Wnt-driven tumor biology. The study further shows that pathway inhibition can remodel the tumor immune microenvironment by reducing regulatory T cells and increasing dendritic and cytotoxic T-cell responses, thereby improving sensitivity to PD-1 blockade.

• Aurora A in Retinoblastoma: Evidence for Targeting

  2026-08-14

  This 2024 study identifies broad Aurora kinase A overexpression in human retinoblastoma and links it to histopathologic features associated with aggressive disease and chemotherapy resistance. By combining patient-tissue analysis with genetic and pharmacologic perturbation in cellular, patient-derived, xenograft, and enucleated-tumor models, the work provides a disease-specific rationale for studying AURKA dependence in retinoblastoma.

• Human Cortical Interneurons for Durable Seizure Control

  2026-08-14

  The reference study shows that chemically matured, migratory human cortical interneurons can integrate into epileptic circuits, provide durable seizure and behavioral benefits, and avoid density-dependent over-inhibition. Its combination of transplantation, closed-loop optogenetics, and monosynaptic tracing offers a mechanistic framework for evaluating safety, connectivity, and therapeutic control in stem cell-based epilepsy research.

• KX2-361 Blocks BoNT/A SNAP-25 Cleavage

  2026-08-13

  The reference study identifies KX2-361, a tirbanibulin analog, as a cell-active inhibitor of botulinum neurotoxin serotype A in both pre- and post-intoxication models. Its activity in motor neurons, effects on the BoNT/A light-chain system, and supporting docking results establish a mechanistic lead for developing treatments that may act after neuronal toxin entry.

• Cisplatin Workflows for Cancer Research

  2026-08-13

  Build reproducible CDDP experiments that connect DNA crosslinking to viability, apoptosis, oxidative stress, and chemoresistance. This practical guide adapts Cisplatin for gastric cancer stem cell studies, mechanistic assays, and tumor growth inhibition in xenograft models.

• AMPK–SQSTM1 Feedback in Metabolic Stress

  2026-08-12

  The 2024 Autophagy study identifies SQSTM1/p62 as a central integrator linking lysosomal stress, AMPK activation, autophagy, and NFE2L2/NRF2-dependent antioxidant defense. Its double-positive AMPK–SQSTM1 feedback model helps explain metabolic adaptation in STK11/LKB1- and KEAP1-altered lung cancer, while also defining experimental controls for studying nutrient stress and redox signaling.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-08-12

  FITC-Concanavalin A (ConA) Conjugate provides a direct fluorescent readout of accessible α-D-glucose and α-D-mannose moieties on glycoproteins and glycolipids, supporting cell-surface carbohydrate detection, microscopy, and flow cytometry. It should be used in defined carbohydrate-binding workflows, not as a general protein stain or a method for identifying non-glycan targets.

• 4-Hydroxytamoxifen: Practical Workflow Guide

  2026-08-11

  4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled in vitro workflows, including breast cancer research, prostate cancer research, and cardiac myocyte calcium handling studies. It should not be selected for protocols requiring aqueous or ethanol solubility, and its dossier context should not be treated as a validated dose or efficacy protocol without independent optimization.

• Sulfachloropyridazine: From DHPS to Microbiome Insight

  2026-08-11

  Sulfachloropyridazine is more than a conventional sulfonamide antibacterial agent. By connecting DHPS inhibition with antimicrobial susceptibility testing, microbiome profiling, metabolomics, and in vivo infection models, translational researchers can use this research-grade compound to distinguish direct antibacterial activity from broader ecosystem effects.

• Pioglitazone Workflows for PPARγ Research

  2026-08-10

  Pioglitazone is a practical PPARγ agonist for connecting metabolic signaling with macrophage polarization, intestinal inflammation, beta-cell stress, and neurodegeneration models. This workflow-centered guide covers assay design, DSS-induced inflammatory bowel disease studies, formulation, controls, and troubleshooting.

• Measuring Drug Response Beyond Cell Viability

  2026-08-09

  Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability are not interchangeable measures of anticancer drug response. By separating growth inhibition from cell killing and considering their timing, the study provides a more interpretable framework for in vitro pharmacology and for designing follow-up experiments.

16408 records 1/1094 page Next 12345 下5页 Last page